Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity

March 5, 2020 updated by: Gülin Öztürk Özkan, Istanbul Medeniyet University

Determination of the Relationship Between Nesfatin-1 Levels and Energy Intake Levels of Patients With Type 2 Diabetes, Insulin Resistance and Obesity

This research was planned to determine the level of nesfatin-1, known as satiety hormone, in type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a relationship between patients' energy intake levels. Additionally, it was aimed to evaluate the relationship between patients' nesfatin-1 values and serum glucose, insulin, lipid concentrations.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

Nesfatin-1 levels of patients with type 2 diabetes, insulin resistance and obesity will be measured. In addition, patients' daily food consumption will be taken and the amount of energy they receive will be calculated daily. The relationship between the level of nesfatin-1 in the blood and the energy received will be examined.

Study Type

Interventional

Enrollment (Anticipated)

180

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Gülin Öztürk Özkan, Assis Prof
  • Phone Number: 02162803333
  • Email: glnzturk@gmail.com

Study Locations

      • İstanbul, Turkey
        • Recruiting
        • Haydarpasa Numune Education and Research Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 79 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Type 2 diabetes
  • Insulin resistance
  • Obesity disease

Exclusion Criteria:

  • Pediatric individuals
  • All patients who are hospitalized,
  • Liver disease
  • Cancer patients
  • Disease related to the gastrointestinal tract
  • Nephrological disease such as chronic kidney failure, acute kidney failure, nephrotic syndrome
  • Neurological disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: DIAGNOSTIC
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: Type 2 Diabetes group
In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
OTHER: Insulin resistance group
In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level
OTHER: Obesity group
In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nefratin-1 in type 2 diabetes
Time Frame: 1 day (Blood will be drawn from patients once)
Blood will be drawn from type 2 diabates patients after 12 hours of fasting (n=45)
1 day (Blood will be drawn from patients once)
Nefratin-1 in obesity
Time Frame: 1 day (Blood will be drawn from patients once)
Blood will be drawn from obesity patients after 12 hours of fasting (n=45)
1 day (Blood will be drawn from patients once)
Nefratin-1 in insulin resistance
Time Frame: 1 day (Blood will be drawn from patients once)
Blood will be drawn from insulin resistance patients after 12 hours of fasting (n=45)
1 day (Blood will be drawn from patients once)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Gülin Öztürk Özkan, Assis Prof, Istanbul Medeniyet University
  • Study Director: Kadir Kayataş, associate professor, Haydarpasa Numune Education and Research Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

March 2, 2020

Primary Completion (ANTICIPATED)

March 31, 2021

Study Completion (ANTICIPATED)

March 31, 2021

Study Registration Dates

First Submitted

February 10, 2020

First Submitted That Met QC Criteria

March 5, 2020

First Posted (ACTUAL)

March 6, 2020

Study Record Updates

Last Update Posted (ACTUAL)

March 6, 2020

Last Update Submitted That Met QC Criteria

March 5, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Nesfatin-1

Subscribe